<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01169077</url>
  </required_header>
  <id_info>
    <org_study_id>08-0008</org_study_id>
    <secondary_id>N01AI80005C</secondary_id>
    <nct_id>NCT01169077</nct_id>
  </id_info>
  <brief_title>EP1300 Polyepitope DNA Vaccine Against Plasmodium Falciparum Malaria</brief_title>
  <official_title>A Phase I, Randomized, Controlled Dosage-Escalation Study of the Safety and Reactogenicity of the EP1300 Polyepitope DNA Vaccine Against Plasmodium Falciparum Malaria Administered Via Electroporation to Healthy Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institute of Allergy and Infectious Diseases (NIAID)</source>
  <brief_summary>
    <textblock>
      Malaria, a disease responsible for over one million deaths per year, is caused by a germ&#xD;
      spread by mosquito bites. The purpose of this study is to evaluate a vaccine designed for the&#xD;
      prevention of malaria caused by the parasite, Plasmodium falciparum, and to evaluate the&#xD;
      device used to give the vaccine. This study will provide information on how safe, effective,&#xD;
      and tolerable the vaccine is in healthy adults. The participants will be assigned, by chance,&#xD;
      to receive 3 doses/shots of the vaccine or a placebo (substance that contains no medication)&#xD;
      by injection in the upper arm. Study participants will include 39 healthy adults aged 18-40&#xD;
      years who have not been exposed to malaria and who will enroll at the Emory Vaccine and&#xD;
      Treatment Evaluation Unit in Atlanta, Georgia. Study procedures include physical exams and&#xD;
      several blood samples. Participants will be involved in the study for approximately seven and&#xD;
      one half months.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Malaria is a mosquito-borne disease caused by protozoan parasites of the genus Plasmodium&#xD;
      (P.). It is estimated that there are 350-500 million clinical cases of malaria per year,&#xD;
      accounting for over one million deaths. The majority of deaths occur among children under&#xD;
      five years of age in Africa, especially in those areas with poor access to healthcare&#xD;
      services. Severe disease occurs most frequently with P. falciparum, at least partially due to&#xD;
      its ability to infect a higher percentage of erythrocytes and to adhere to capillary walls.&#xD;
      Development of a safe and effective vaccine targeting P. falciparum is a major public health&#xD;
      goal. To be truly effective in the general population, a vaccine should induce responses&#xD;
      targeting &quot;immunologically&quot; conserved regions. Epitope-based vaccines represent a very&#xD;
      logical approach to this problem because they can be designed to focus immune responses only&#xD;
      on conserved epitopes. The proposed clinical trial will be the first to evaluate a novel&#xD;
      deoxyribonucleic acid (DNA)-based, polyepitope vaccine against P. falciparum malaria. The&#xD;
      study will be conducted as a phase I, randomized, prospective, controlled, single-center,&#xD;
      dose-escalating trial. This study is designed to provide information regarding the safety and&#xD;
      tolerability of the EP (Electroporation) 1300 vaccine that will allow further development of&#xD;
      the vaccine in future studies. Immunogenicity will be assessed in a preliminary fashion as a&#xD;
      secondary endpoint. The primary objective of this study is to evaluate the safety,&#xD;
      reactogenicity and tolerability of the EP1300 (DNA) vaccine administered via electroporation&#xD;
      in healthy adult volunteers. The secondary objectives are to obtain preliminary&#xD;
      immunogenicity data for the EP1300 polyepitope DNA vaccine as assessed by interferon-gamma&#xD;
      enzyme-linked immunospot assay and to assess the tolerability of the administration procedure&#xD;
      in healthy volunteers. Thirty-nine healthy adults aged 18 through 40 who have no previous&#xD;
      history of malaria exposure or infection, no history of travel to malaria-endemic areas, and&#xD;
      who have not received vaccines for malaria infection will be enrolled in this study. Subjects&#xD;
      will be randomized to receive 3 doses of either the DNA vaccine or normal saline placebo at&#xD;
      day 0, 28, and 56. DNA doses will be administered in dose-escalating fashion from 0.25 mg to&#xD;
      4 mg. Dose escalation will proceed following a review of all safety data up to and including&#xD;
      the 2-week safety data time point following the second immunization in the prior dosage&#xD;
      group; review includes participation by Division of Microbiology and Infectious Diseases and&#xD;
      the Safety Monitoring Committee.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2010</start_date>
  <completion_date type="Actual">July 2012</completion_date>
  <primary_completion_date type="Actual">July 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The number of serious adverse events considered associated with the vaccine.</measure>
    <time_frame>Reported at any point during follow-up.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The number of subjects reporting solicited systemic adverse events of severity (grade 3) or higher.</measure>
    <time_frame>Within 14 days after receiving any dose of vaccine.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The number of subjects experiencing spontaneous adverse events of severity (grade 3) or higher and considered associated with the vaccine.</measure>
    <time_frame>Reported at any point during follow-up.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The number of subjects reporting local reactogenicity of severity (grade 3) or higher.</measure>
    <time_frame>Within 14 days after receiving any dose of vaccine.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Responses to tolerability questionnaire used to document subject feedback of electroporation mediated DNA vaccine delivery; proportion of subjects judging the procedure to be suitable for use in context of a prophylactic malaria vaccine.</measure>
    <time_frame>Day 0, 28 and 56.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antibody titers in serum measured against malaria circumsporozoite protein [Geometric Mean Titer and individual log Enzyme-Linked Immunosorbent Assay (ELISA) units] for subjects in groups II and III.</measure>
    <time_frame>Day 0, 42, and 70.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sample number showing positive falciparum-specific responses, Geometric Mean Titer spot-forming cells/million peripheral blood mononuclear cell per cohort, subject frequency per cohort with at least 1 positive response.</measure>
    <time_frame>Days 0, 42 and 70.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Interferon-gamma Enzyme-Linked Immunospot Assay (ELISPOT) assay.</measure>
    <time_frame>Days 0, 42 and 70.</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">39</enrollment>
  <condition>Plasmodium Falciparum Malaria</condition>
  <arm_group>
    <arm_group_label>Group I: 0.25 mg EP-1300</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ten subjects will receive 3 immunizations of EP1300, 0.25 mg, on Day 0, Day 28 and Day 56. Three control subjects in this group will receive placebo injections at the same timepoints.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group II: 1.0 mg EP-1300</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ten subjects will receive 3 immunizations of EP1300, 1.0 mg, on Day 0, Day 28 and Day 56. Three control subjects in this group will receive placebo injections at the same timepoints.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group III: 4.0 mg EP-1300</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ten subjects will receive 3 immunizations of EP1300, 4.0 mg, Day 0, Day 28 and Day 56. Three control subjects in this group will receive placebo injections at the same timepoints.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Injections of normal saline to be used as control; given at Days 0, 28, and 56. Administered via electroporation, using a DNA vaccine delivery device, in the deltoid.</description>
    <arm_group_label>Group I: 0.25 mg EP-1300</arm_group_label>
    <arm_group_label>Group II: 1.0 mg EP-1300</arm_group_label>
    <arm_group_label>Group III: 4.0 mg EP-1300</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>EP-1300</intervention_name>
    <description>Single DNA plasmid dissolved in phosphate-buffered saline (PBS). Dose levels: 0.25, 1 and 4 mg based on DNA content, administered on Days 0, 28 and 56 via electroporation using a DNA vaccine delivery device, in the deltoid.</description>
    <arm_group_label>Group I: 0.25 mg EP-1300</arm_group_label>
    <arm_group_label>Group II: 1.0 mg EP-1300</arm_group_label>
    <arm_group_label>Group III: 4.0 mg EP-1300</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Men and women, 18 through 40 years old, who deny exposure to or infection with malaria&#xD;
             or prior participation in a malaria vaccine study.&#xD;
&#xD;
          -  In good health, defined as a person who consents to participate in the trial, agrees&#xD;
             to not donate blood until 6 months following the last blood draw in the protocol, and&#xD;
             whose clinical laboratory assessments are within parameters as specified in this&#xD;
             protocol in Appendix C, (Acceptable Screening Laboratory Ranges). (Women of&#xD;
             childbearing potential (not surgically sterile or postmenopausal for &gt;/= 1 year) must&#xD;
             not be pregnant as indicated by a negative pregnancy test (urine or serum) within 24&#xD;
             hours prior to vaccine administration.&#xD;
&#xD;
          -  Women of childbearing potential who are at risk of becoming pregnant must agree to&#xD;
             practice adequate contraception (i.e., barrier methods in conjunction with spermicidal&#xD;
             gel, abstinence, monogamous relationship with vasectomized partner, intrauterine&#xD;
             devices, Depo-Provera, Norplant, oral contraceptives, contraceptive patches or other&#xD;
             licensed, effective methods) until 30 days following receipt of the last dose of&#xD;
             vaccine.&#xD;
&#xD;
          -  Able to understand and comply with planned study procedures.&#xD;
&#xD;
          -  Able to provide informed consent prior to initiation of any study procedures and be&#xD;
             available for all study visits.&#xD;
&#xD;
          -  Have access to a telephone.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior history of travel to a malaria-endemic area.&#xD;
&#xD;
          -  History of previous malaria infection.&#xD;
&#xD;
          -  Planned travel to a malaria-endemic area during the course of the study.&#xD;
&#xD;
          -  History of splenectomy.&#xD;
&#xD;
          -  Known hypersensitivity to components of the vaccine (deoxyribonucleic acid,&#xD;
             phosphate-buffered saline, potassium dihydrogen phosphate, sodium hydrogen phosphate)&#xD;
             or to kanamycin or other aminoglycoside antibiotics.&#xD;
&#xD;
          -  Is female of child-bearing potential who is breastfeeding or intends to become&#xD;
             pregnant during the study period up to 30 days following receipt of the last dose of&#xD;
             vaccine.&#xD;
&#xD;
          -  Has immunosuppression as a result of an underlying illness or treatment with&#xD;
             immunosuppressive or cytotoxic drugs, or use of anticancer radiation therapy within&#xD;
             the preceding 60 months.&#xD;
&#xD;
          -  History of significant cardiac abnormality and/or abnormal baseline electrocardiogram&#xD;
             (ECG) readout, and/or history of arrhythmia, including any cardiac pre-excitation&#xD;
             syndromes (such as Wolff Parkinson White) or other cardiac syndromes or diseases (such&#xD;
             as congestive heart failure) associated with arrhythmias, a history of syncopal&#xD;
             episodes, and/or family history of prolonged QTc syndrome.&#xD;
&#xD;
          -  Subjects with a seizure disorder, except for those who have been seizure free for 5&#xD;
             years or are felt to be at low risk for seizure as determined by their neurologist&#xD;
             (the effects of electric field generation near sites where the threshold of field&#xD;
             sensitivity is low is unknown).&#xD;
&#xD;
          -  Subjects with hemophilia, thrombocytopenia, bleeding or clotting disorders, muscular&#xD;
             atrophy or muscular/neuromuscular degenerative disorders.&#xD;
&#xD;
          -  Presence of any implanted any electronic stimulation device, such as cardiac demand&#xD;
             pacemakers, automatic implantable cardiac defibrillator, nerve stimulators, or deep&#xD;
             brain stimulators.&#xD;
&#xD;
          -  Individuals in which a skin-fold measurement of the cutaneous and subcutaneous tissue&#xD;
             for all eligible injection sites (deltoid muscles with intact lymph drainage) exceeds&#xD;
             40 millimeters.&#xD;
&#xD;
          -  Presence of surgical or traumatic metal implant in the upper limb and/or upper torso.&#xD;
&#xD;
          -  Subjects with tattoos, lesions, rashes, scars or tumors at the proposed sites of&#xD;
             administration.&#xD;
&#xD;
          -  Has an active neoplastic disease (excluding non-melanoma skin cancer or prostate&#xD;
             cancer that is stable in the absence of therapy) or a history of any hematologic&#xD;
             malignancy. Active is defined as: no neoplastic disease or treatment for neoplastic&#xD;
             disease within the past 5 years.&#xD;
&#xD;
          -  Has long-term use (greater than 2 weeks) of oral or parenteral steroids, or high-dose&#xD;
             inhaled steroids (greater than 800 micrograms per day of beclomethasone dipropionate&#xD;
             or equivalent) within the preceding 6 months (nasal and topical steroids are allowed).&#xD;
&#xD;
          -  Has a history of receiving immunoglobulin or other blood products within the 3 months&#xD;
             prior to enrollment in this study.&#xD;
&#xD;
          -  Has received any other licensed vaccines within 2 weeks (for inactivated vaccines) or&#xD;
             4 weeks (for live vaccines) prior to enrollment in this study, or plans to receive any&#xD;
             other licensed vaccines within 2 weeks (for inactivated vaccines) or 4 weeks (for live&#xD;
             vaccines) following each study vaccination.&#xD;
&#xD;
          -  Has an acute or chronic medical condition that, in the opinion of the investigator,&#xD;
             would render vaccination unsafe or would interfere with the evaluation of responses&#xD;
             (this includes, but is not limited to: known cardiac arrhythmia or coronary artery&#xD;
             disease, known chronic liver disease, significant renal disease, unstable or&#xD;
             progressive neurological disorders, diabetes mellitus, and transplant recipients,&#xD;
             bleeding disorders, or skin conditions, e.g. psoriasis).&#xD;
&#xD;
          -  Has a history of severe reactions suggesting anaphylaxis following any previous&#xD;
             vaccination.&#xD;
&#xD;
          -  Has an acute illness or has an oral temperature greater than 99.9 degrees Fahrenheit&#xD;
             (37.7 degrees Celsius) within 3 days prior to enrollment.&#xD;
&#xD;
          -  Has received an experimental agent (vaccine, drug, biologic, device, blood product, or&#xD;
             medication) within 1 month prior to enrollment in this study, or expect to receive an&#xD;
             experimental agent during the study period.&#xD;
&#xD;
          -  Has any condition that would, in the opinion of the site principal investigator, place&#xD;
             the subject at an unacceptable risk of injury or render the subject unable to meet the&#xD;
             requirements of the protocol.&#xD;
&#xD;
          -  Has a diagnosis of schizophrenia, bipolar disease or other severe (disabling) chronic&#xD;
             psychiatric diagnosis.&#xD;
&#xD;
          -  Has been hospitalized for psychiatric illness, history of suicide attempt or&#xD;
             confinement for danger to self or others.&#xD;
&#xD;
          -  Is receiving psychiatric drugs (aripiprazole, clozapine, ziprasidone, haloperidol,&#xD;
             molindone, loxapine, thioridazine, thiothixene, pimozide, fluphenazine, risperidone,&#xD;
             mesoridazine, quetiapine, trifluoperazine, trifluopromazine, chlorprothixene,&#xD;
             chlorpromazine, perphenazine, olanzapine, carbamazepine, divalproex sodium, lithium&#xD;
             carbonate or lithium citrate). Subjects who are receiving a single antidepressant drug&#xD;
             and are stable for at least 3 months prior to enrollment without decompensating are&#xD;
             allowed enrollment into the study.&#xD;
&#xD;
          -  Positive serology for human immunodeficiency virus, hepatitis B, or hepatitis C&#xD;
             infection.&#xD;
&#xD;
          -  Abnormal values on clinical safety laboratory tests obtained during screening.&#xD;
&#xD;
          -  Has a history of alcohol or drug abuse in the 5 years prior to enrollment.&#xD;
&#xD;
          -  Has a history of Guillain-Barr√© syndrome.&#xD;
&#xD;
          -  Has any condition that the investigator believes may interfere with successful&#xD;
             completion of the study.&#xD;
&#xD;
          -  Plans to enroll in another clinical trial at any time during the study period.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Emory Children's Center - Pediatric Infectious Diseases</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2012</verification_date>
  <study_first_submitted>July 22, 2010</study_first_submitted>
  <study_first_submitted_qc>July 22, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 23, 2010</study_first_posted>
  <last_update_submitted>November 15, 2012</last_update_submitted>
  <last_update_submitted_qc>November 15, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 16, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>malaria, plasmodium falciparum, electroporation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Malaria</mesh_term>
    <mesh_term>Malaria, Falciparum</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

